Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > FGF R4


Brief Information

Name:Fibroblast growth factor receptor 4
Target Synonym:EC 2.7.10,EC:,Fibroblast growth factor receptor 4,CD334,FGFR4,TKF,JTK2,Tyrosine Kinase Related To Fibroblast Growth Factor Receptor,Hydroxyaryl-Protein Kinase,Protein-Tyrosine Kinase,Tyrosylprotein Kinase,CD334 Antigen,EC,FGFR-4,Receptor, Fibroblast Growth Factor, Type 4
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:19
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data


Human FGF R4, Fc Tag (Cat. No. FG4-H5253) immobilized on CM5 Chip can bind Human FGF-4 Protein, His Tag (Cat. No. FG4-H51H3) with an affinity constant of 1.48 μM as determined in a SPR assay (Biacore 8K) (QC tested).

FGF R4 MALS images

The purity of Human FGF R4, Fc Tag (Cat. No. FG4-H5253) is more than 90% and the molecular weight of this protein is around 145-175 kDa verified by SEC-MALS.

Synonym Name



Fibroblast growth factor receptor 4(FGFR4) is also known as CD334, JTK2,  hydroxyaryl-protein kinase, TKF, protein-tyrosine kinase . The FGFR4 gene provides instructions for making a protein called fibroblast growth factor receptor 4. This protein is part of a family of fibroblast growth factor receptors that share similar structures and functions. These receptor proteins play a role in important processes such as cell division, regulating cell growth and maturation, formation of blood vessels, wound healing, and embryo development.The FGFR4 protein interacts with specific growth factors to conduct signals from the environment outside the cell to the nucleus. The nucleus responds to these signals by switching on or off appropriate genes that help the cell adjust to changes in the environment. In response, the cell might divide, move, or mature to take on specialized functions. Although specific functions of FGFR4 remain unclear, studies indicate that the gene is involved in muscle development and the maturation of bone cells in the skull. The FGFR4 gene may also play a role in the development and maintenance of specialized cells (called foveal cones) in the light-sensitive layer (the retina) at the back of the eye.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Lenvatinib Mesylate MK-7902; ER-203492-00; E-7080 Approved Eisai Co Ltd Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 United States Thyroid Neoplasms Eisai Inc 2015-02-13 Carcinoma, Adenoid Cystic; Paraganglioma; Melanoma; Thyroid Cancer, Papillary; Carcinoma, Hepatocellular; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Glioma; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Breast Neoplasms; Cholangiocarcinoma; Osteosarcoma; Solid tumours; Neuroendocrine Tumors; Adenocarcinoma, Follicular; Liver Diseases; Thyroid Carcinoma, Anaplastic; Adenocarcinoma of Lung; Kidney Diseases; Neoplasms; Pheochromocytoma; Esophageal Neoplasms; Renal Insufficiency; Carcinoma, Renal Cell; Liver Neoplasms; Ovarian Neoplasms; Biliary Tract Neoplasms Details
Futibatinib TAS-120 Approved Taiho Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd LYTGOBI United States Cholangiocarcinoma Taiho Oncology Inc 2022-09-30 Biliary Tract Neoplasms; Solid tumours; Bone Marrow Neoplasms; Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Central Nervous System Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Sarcoma; Endometrial Neoplasms; Lymphoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
Erdafitinib G-024; JNJ-493; JNJ-42756493; TAR-210; 890E37NHMV Approved Astex Pharmaceuticals Inc Balversa United States Carcinoma, Transitional Cell Janssen Biotech Inc 2019-04-12 Carcinoma, Squamous Cell; Breast Neoplasms; Neuroblastoma; Sarcoma; Prostatic Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Histiocytic Sarcoma; Hepatic Insufficiency; Lymphoma; Lymphoma, Non-Hodgkin; Histiocytosis, Langerhans-Cell; Carcinoma, Neuroendocrine; Neoplasms, Neuroepithelial; Glioma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Xanthogranuloma, Juvenile; Neuroectodermal Tumors, Primitive, Peripheral; Neoplasms, Germ Cell and Embryonal; Carcinoma, Transitional Cell; Medulloblastoma; Rhabdomyosarcoma; Hematologic Neoplasms; Ependymoma; Bone metastases; Stomach Neoplasms; Carcinoma; Esophageal Neoplasms; Rhabdoid Tumor; Hepatoblastoma; Solid tumours; Neoplasms; Wilms Tumor; Glioblastoma; Urinary Bladder Neoplasms; Central Nervous System Neoplasms; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Sarcoma, Ewing; Osteosarcoma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Rogaratinib BAY-1163877 Phase 3 Clinical Bayer AG Solid tumours; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Breast Neoplasms; Gastrointestinal Stromal Tumors; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung Details
SC-0011 SC-0011 Phase 3 Clinical Shijiazhuang Zhikang Hongren New Drug Development Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung Details
AUR-109 ODM-203; AUR-109 Phase 2 Clinical Orion Corp Ovarian Neoplasms; Liver Neoplasms; Solid tumours; Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Pulmonary Fibrosis; Breast Neoplasms; Lung Neoplasms Details
Fisogatinib BLU-554; CS-3008 Phase 2 Clinical Blueprint Medicines Corp Carcinoma, Hepatocellular Details
EVER-4010001 EVER-4010001 Phase 2 Clinical EverNov Medicines (Zhuhai Hengqin) Co Ltd Solid tumours Details
Gunagratinib ICP-192 Phase 2 Clinical Beijing Tiancheng Pharmaceutical Technology Co Ltd Solid tumours; Biliary Tract Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Cholangiocarcinoma; Lung Neoplasms Details
Roblitinib FGF-401; NVP-FGF401 Phase 2 Clinical Novartis Pharma Ag Solid tumours; Neoplasms; Carcinoma, Hepatocellular Details
Irpagratinib ABSK-011 Phase 2 Clinical ABbisko Therapeutics Co Ltd Solid tumours; Liver Neoplasms; Carcinoma, Hepatocellular Details
BPI-43487 BPI-43487 Phase 1 Clinical Betta Pharmaceuticals Co Ltd Biliary Tract Neoplasms; Solid tumours; Carcinoma, Hepatocellular Details
HS-236 HS-236 Phase 1 Clinical Zhejiang Hisun Pharmaceutical Co Ltd Solid tumours Details
HS-10340 HS-10340 Phase 1 Clinical Changzhou Hengbang Pharmaceutical Co Ltd, Shanghai Hansoh Biomedical Co Ltd, Jiangsu Hansoh Pharmaceutical Group Co Ltd Solid tumours Details
ICP-105 ICP-105 Phase 1 Clinical Nanjing Tianyin Jianhua Pharmaceutical Technology Co Ltd, Beijing Tiancheng Pharmaceutical Technology Co Ltd, Beijing Innocare Pharma Tech Co Ltd Liver Neoplasms; Solid tumours Details
ZSP-1241 ZSP-1241 Phase 1 Clinical Guangdong Zhongsheng Pharmaceutical Co Ltd, Wuxi Apptec Co Ltd Biliary Tract Neoplasms; Liver Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma; Cholangiocarcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular Details
H3B-6527 H3B-6527 Phase 1 Clinical H3 Biomedicine Inc Liver Neoplasms; Carcinoma, Hepatocellular Details
SYHX-2005 SYHX-2005; SYHX2005 Phase 1 Clinical Cspc Ouyi Pharmaceutical Co Ltd Solid tumours Details
JAB-6343 Phase 1 Clinical Jacobio Pharmaceuticals Co Ltd Solid tumours Details
SY-4798 Phase 1 Clinical Shouyao Holding (Beijing) Co Ltd Solid tumours Details
ABSK-012 ABSK-012; ABSK012 Phase 1 Clinical ABbisko Therapeutics Co Ltd Solid tumours Details
LY-2874455 LY-2874455 Phase 1 Clinical Eli Lilly And Company Neoplasms; Leukemia, Myeloid, Acute Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message